Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 402

1.

Reversal of refractory septic shock with drotrecogin alpha (activated).

Vieillard-Baron A, Caille V, Charron C, Belliard G, Aegerter P, Page B, Jardin F.

Intensive Care Med. 2009 Jul;35(7):1204-9. doi: 10.1007/s00134-009-1538-9. Epub 2009 Jun 16.

PMID:
19529911
2.

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.

Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, Charpentier J, Belger M, Cobas-Meyer M, Maier C, Mignini MA, Janes J.

Intensive Care Med. 2009 Jul;35(7):1187-95. doi: 10.1007/s00134-009-1436-1. Epub 2009 Mar 5. Erratum in: Intensive Care Med. 2009 Jul;35(7):1319-21.

PMID:
19263034
3.

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.

Spapen H, Nguyen DN, Troubleyn J, Huyghens L, Schiettecatte J.

Crit Care. 2010;14(2):R54. doi: 10.1186/cc8947. Epub 2010 Apr 7.

4.

Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.

Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F.

Crit Care Med. 2007 Jan;35(1):69-75.

PMID:
17133181
5.

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.

Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D.

Intensive Care Med. 2007 Mar;33(3):426-34. Epub 2007 Feb 15.

PMID:
17325836
6.

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

Crit Care Med. 2004 Nov;32(11):2207-18.

PMID:
15640632
7.

Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.

Camporota L, Corno E, Menaldo E, Smith J, Lei K, Beale R, Wyncoll D.

Crit Care. 2008;12(6):R163. doi: 10.1186/cc7163. Epub 2008 Dec 18.

8.

Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.

Albuali WH, Singh RN, Fraser DD, Scott LA, Kornecki A.

Saudi Med J. 2005 Aug;26(8):1289-92.

PMID:
16127532
9.
10.

Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.

Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK, Cooper LM.

Curr Med Res Opin. 2007 Jan;23(1):235-44.

PMID:
17207305
11.

Evolution of lactate/pyruvate and arterial ketone body ratios in the early course of catecholamine-treated septic shock.

Levy B, Sadoune LO, Gelot AM, Bollaert PE, Nabet P, Larcan A.

Crit Care Med. 2000 Jan;28(1):114-9.

PMID:
10667509
12.

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

PMID:
17084715
13.

Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.

Póvoa P, Salluh JI, Martinez ML, Guillamat-Prats R, Gallup D, Al-Khalidi HR, Thompson BT, Ranieri VM, Artigas A.

Crit Care. 2015 Apr 28;19:193. doi: 10.1186/s13054-015-0921-x.

14.

Activated protein C and septic shock: a propensity-matched cohort study*.

Rimmer E, Kumar A, Doucette S, Marshall J, Dial S, Gurka D, Dellinger RP, Sharma S, Penner C, Kramer A, Wood K, Ronald J, Kumar A, Turgeon AF, Houston DS, Zarychanski R; Co-operative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group.

Crit Care Med. 2012 Nov;40(11):2974-81. doi: 10.1097/CCM.0b013e31825fd6d9.

PMID:
22932397
15.

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

Hodder RV, Hall R, Russell JA, Fisher HN, Lee B.

Crit Care. 2009;13(3):R78. doi: 10.1186/cc7893. Epub 2009 May 20.

16.

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

Crit Care. 2006;10(3):R74. Epub 2006 May 9.

17.

Corticosteroids and human recombinant activated protein C for septic shock.

Colin G, Annane D.

Clin Chest Med. 2008 Dec;29(4):705-12, x. doi: 10.1016/j.ccm.2008.06.009. Review.

PMID:
18954704
18.

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.

PMID:
18158435
19.

A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.

Crum NF, Groff HL, Parrish JS, Ring W.

Clin Infect Dis. 2004 Dec 1;39(11):e122-3. Epub 2004 Nov 9.

20.

Drotrecogin alfa (activated) in adults with septic shock.

Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group.

N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22.

Items per page

Supplemental Content

Write to the Help Desk